Ambrx Biopharma, Inc. - Common Stock (NY:AMAM)

N/A UNCHANGED

Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ambrx Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Ambrx Biopharma's Oncology Pipeline Is Underappreciated, Analyst Initiating Coverage Says ↗

May 19, 2023

Cantor Fitzgerald initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) with an Overweight rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2023 ↗

May 19, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About Ambrx Biopharma ↗

May 19, 2023

Via Benzinga

Why Shares of Ambrx Biopharma Jumped This Week ↗

May 18, 2023

The company reported data on its clinical programs at two conferences this week.

Via The Motley Fool

Ambrx Biopharma Highlights Preclinical Data From Studies in Kidney, Prostate Cancer ↗

April 19, 2023

Via Benzinga

Why Sunrise New Energy Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket ↗

May 17, 2023

Gainers

Via Benzinga

$59M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying ↗

April 21, 2023

Although US stocks closed lower on Thursday, there were a few notable insider trades.

Via Benzinga

Over $25M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying ↗

April 18, 2023

Although US stocks closed higher on Monday, there were a few notable insider trades.

Via Benzinga

7 Cheap Stocks That Are Worth Your Attention ↗

April 03, 2023

Finding cheap stocks that are worth an investment can be tricky, but the Portfolio Grader is a tool you can use to narrow the field.

Via InvestorPlace

7 Risky Stocks That Are Worth the Stretch ↗

March 31, 2023

If you're going to invest in risky stocks, it's important for you to first understand your risk tolerance. These names will get you started.

Via InvestorPlace

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...

Via Benzinga

5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions ↗

March 13, 2023

Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits...

Via Benzinga

Ambrx Raises $78 Million and Completes its ATM Program

March 13, 2023

From Ambrx, Inc.

Via Business Wire

Week In Review: Sino Biopharma Acquires F-Star For $161 Million After US Approval ↗

March 11, 2023

Sino Biopharma was approved to close its $161 million all-cash acquisition of F-Star. The purchase didn't look like would happen after it was held up for nine months by the US government’s Committee on...

Via Talk Markets

Why Shares of Ambrx Biopharma Fell Tuesday ↗

March 07, 2023

After getting a bump on Monday for its switch to the Nasdaq Stock Market, there was a bit of a correction.

Via The Motley Fool

Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 07, 2023

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 07, 2023

Via Benzinga

Dow Sheds Over 300 Points After Powell Comments ↗

March 07, 2023

Federal Reserve Chair Jerome Powell's latest comments are dragging down sentiment on Wall Street.

Via Talk Markets

Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy

March 07, 2023

Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy

Via MarketBeat

Topics Initial Public Offering

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 07, 2023

Via Benzinga

Why Adial Pharmaceuticals Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket ↗

March 07, 2023

Gainers

Via Benzinga

Nutanix, Cara Therapeutics, Tremor International And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

March 07, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Tesla, Amazon, Ambrx, BridgeBio, Azul: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

March 06, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 06, 2023

Via Benzinga

Ambrx to Commence Trading on Nasdaq

March 06, 2023

From Ambrx, Inc.

Via Business Wire

EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In February — Including Tesla, Apple And A Surging AI Name ↗

March 01, 2023

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 01, 2023

Via Benzinga

ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results

March 01, 2023

From Ambrx, Inc.

Via Business Wire

Top 5 Health Care Stocks That You May Want To Dump In Q1 2023 ↗

February 28, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 27, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.